Skip to main content

CD5+ B lymphocytes in high-risk islet cell antibody-positive and newly diagnosed IDDM subjects.

Publication ,  Journal Article
Schatz, DA; Lang, F; Cantor, AB; Riley, WJ; Maclaren, NK; Sleasman, JW; Barrett, DJ
Published in: Diabetes
October 1991

Human CD5+ B lymphocytes produce autoantibodies that bind to self- and exogenous antigens. Extremely high percentages of CD5+ B lymphocytes are present in the fetal and newborn periods, whereas they constitute only a minority of B lymphocytes in healthy adults. Increased percentages of circulating CD5+ lymphocytes have previously been demonstrated in several autoimmune diseases, including rheumatoid arthritis, progressive systemic sclerosis, Graves' disease, and Sjögren's syndrome. We measured the percentages of B lymphocytes that expressed the CD5 determinant in 93 control subjects (age range 1 day to 59 yr, mean +/- 22.6 +/- 17.7 yr), 17 subjects with newly diagnosed insulin-dependent diabetes mellitus (IDDM; range 5-29 yr, mean +/- SD 13 +/- 5.9 yr), 31 high-risk islet cell antibody (ICA)-positive nondiabetic subjects (range 4-45 yr, mean +/- SD 19.8 +/- 14.1 yr), and 13 subjects with IDDM of greater than 5 yr duration (range 10-43 yr, mean +/- SD 24.2 +/- 9.9 yr). We report that CD5+ B-lymphocyte percentages are strikingly age dependent in healthy control subjects, declining progressively from the newborn period to the middle-age years (r = -0.75, P = 0.0001). In ICA+ nondiabetic and recent-onset IDDM subjects less than 29 yr of age, the percentage of circulating CD5+ B lymphocytes fell within the 95% confidence intervals established for control subjects. However, the age-dependent rate of decline in the percentage of CD5+ B lymphocytes within the control range was slower in ICA+ and newly diagnosed IDDM subjects than in control subjects.

Duke Scholars

Published In

Diabetes

DOI

ISSN

0012-1797

Publication Date

October 1991

Volume

40

Issue

10

Start / End Page

1314 / 1318

Location

United States

Related Subject Headings

  • Regression Analysis
  • Middle Aged
  • Islets of Langerhans
  • Infant, Newborn
  • Infant
  • Humans
  • Fluorescent Antibody Technique
  • Flow Cytometry
  • Endocrinology & Metabolism
  • Diabetes Mellitus, Type 1
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Schatz, D. A., Lang, F., Cantor, A. B., Riley, W. J., Maclaren, N. K., Sleasman, J. W., & Barrett, D. J. (1991). CD5+ B lymphocytes in high-risk islet cell antibody-positive and newly diagnosed IDDM subjects. Diabetes, 40(10), 1314–1318. https://doi.org/10.2337/diab.40.10.1314
Schatz, D. A., F. Lang, A. B. Cantor, W. J. Riley, N. K. Maclaren, J. W. Sleasman, and D. J. Barrett. “CD5+ B lymphocytes in high-risk islet cell antibody-positive and newly diagnosed IDDM subjects.Diabetes 40, no. 10 (October 1991): 1314–18. https://doi.org/10.2337/diab.40.10.1314.
Schatz DA, Lang F, Cantor AB, Riley WJ, Maclaren NK, Sleasman JW, et al. CD5+ B lymphocytes in high-risk islet cell antibody-positive and newly diagnosed IDDM subjects. Diabetes. 1991 Oct;40(10):1314–8.
Schatz, D. A., et al. “CD5+ B lymphocytes in high-risk islet cell antibody-positive and newly diagnosed IDDM subjects.Diabetes, vol. 40, no. 10, Oct. 1991, pp. 1314–18. Pubmed, doi:10.2337/diab.40.10.1314.
Schatz DA, Lang F, Cantor AB, Riley WJ, Maclaren NK, Sleasman JW, Barrett DJ. CD5+ B lymphocytes in high-risk islet cell antibody-positive and newly diagnosed IDDM subjects. Diabetes. 1991 Oct;40(10):1314–1318.

Published In

Diabetes

DOI

ISSN

0012-1797

Publication Date

October 1991

Volume

40

Issue

10

Start / End Page

1314 / 1318

Location

United States

Related Subject Headings

  • Regression Analysis
  • Middle Aged
  • Islets of Langerhans
  • Infant, Newborn
  • Infant
  • Humans
  • Fluorescent Antibody Technique
  • Flow Cytometry
  • Endocrinology & Metabolism
  • Diabetes Mellitus, Type 1